NextCure, Inc.

NextCure, Inc. is currently considered overvalued with a valuation downgrade to "does not qualify" due to negative financial metrics, including a Price to Book Value of 0.25, an EV to EBITDA of 0.82, and a concerning ROE of -88.66%, alongside poor stock performance of -39.04% year-to-date compared to the S&P 500's positive return.

As of May 20, 2025, NextCure, Inc. shows a mildly bearish trend due to daily moving averages indicating bearish signals, while mixed indicators suggest a cautious approach overall.

As of March 2022, the management team of NextCure, Inc. includes Dr. David Kabakoff (Independent Chairman), Mr. Michael Richman (President and CEO), Dr. John Houston, Ms. Elaine Jones, Mr. Chau Khuong, Dr. Briggs Morrison, and Mr. Garry Nicholson, all serving as directors. This team oversees the company's strategic direction and operations.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing immunomedicines for cancer and immune-related diseases, with a market cap of $12.66 million and a recent net profit of -$11 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

As of Jun 18, NextCure, Inc. has a market capitalization of 12.66 million, with net sales of 0.00 million and a net profit of -49.52 million over the latest four quarters. Shareholder's funds are 65.47 million, and total assets are 81.92 million as of Dec 24.